$ACRS

Aclaris Therapeutics, Inc.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule and biologic product candidates for immuno-inflammatory diseases. Its pipeline includes bosakitug, an anti-TSLP monoclonal antibody; ATI-052, a bispecific antibody targeting TSLP and IL-4Ra; and oral ITK inhibitors ATI-2138 and ATI-9494. The company also has lepzacitinib, a topical JAK 1/3 inhibitor, and conducts early-stage small-molecule and multispecific antibody discovery. Aclaris uses its proprietary KINect platform for kinase-focused small-molecule discovery and develops antibody candidates through its integrated discovery work. It seeks third-party partners to further develop, obtain marketing approval for, or commercialize its candidates, and may in-license or acquire additional candidates. It licenses global rights to bosakitug and ATI-052 outside Greater China and seeks a global partner for lepzacitinib outside Greater China. Aclaris is headquartered in Wayne, Pennsylvania.

AlphAI earnings readThird Quarter 2026 · NOV 5Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
0
14

No SEC Form 4 filings for $ACRS in the last 30 days.

See all $ACRS insider activity →
Med

H.C. Wainwright reiterates Aclaris stock rating after trial miss

H.C. Wainwright reiterated a Buy rating and $16.00 price target on Aclaris Therapeutics (ACRS) despite its Phase 2 trial for bosakitug missing primary and secondary endpoints. The stock fell 8% to $3.60 post-announcement. Analysts remain bullish on ACRS's broader pipeline, with a Strong Buy consensus and price targets ranging from $4 to $16.

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

ACRS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 15 news stories mentioning ACRS (Aclaris Therapeutics, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 14 bearish.

Recent ACRS coverage spans financial news, earnings and market movers.

What's driving ACRS

AlphAI scores every news story that mentions ACRS with an AI model for sentiment and relevance, and aggregates insider trades from Aclaris Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ACRS

Score
$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMedClinical / regulatory

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSLowAI 8/10Clinical / regulatory· topline data

Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score

$ACRSMedAI 8/10Earnings

Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update ​ - Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results

$ACRSMedAI 8/10

An experimental eczema treatment showed a placebo-adjusted 45% skin-score improvement at week 8.

Aclaris Therapeutics (ACRS) reported Q3 2026 results, highlighting positive Phase 1b trial data for ATI-052 in atopic dermatitis and asthma, with 45% and 59% improvements respectively. The company plans to start a Phase 2b trial for ATI-052 in eosinophilic esophagitis and expects Phase 2b trial initiation for modzatinib in lichen planus in Q4 2026. Aclaris anticipates sufficient cash to fund operations through mid-2029.

Related tickers